SCHEMBL246339

SCHEMBL246339

O=Nc1ccc([AsH2])cc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL234461 0.83 ALDH1A1 (0.58)
SCHEMBL24385153 0.73 ALDH1A1 (0.50)
SCHEMBL10887099 0.73 ALDH1A1 (0.50)
SCHEMBL712641 0.71
SCHEMBL85600 0.69
SCHEMBL11244353 0.69 ALDH1A1 (0.52)
SCHEMBL10016616 0.69 ALDH1A1 (0.46)
SCHEMBL25191034 0.69
SCHEMBL12669931 0.69
SCHEMBL512004 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1156817-B1 CONTROLLING PROTEIN LEVELS IN EUCARYOTIC ORGANISMS WELLSTAT BIOCATALYSIS LLC (US) 2008-08-27 EP claimed
EP-3676282-B1 ANTI-CANCER AGENT UNIV WOLLONGONG (AU) 2024-11-06 EP disclosed
CN-111344298-B Anticancer agent 伍伦贡大学 2024-05-28 CN disclosed
US-11819489-B2 Anti-cancer agent comprising a tumour homing peptide having arsenic bonded to cysteine residues UNIVERSITY OF WOLLONGONG (AU) 2023-11-21 US disclosed
CN-113173952-B Ortho-dithiol reactive therapeutic probe for drug release monitoring and preparation 济南大学 2022-05-24 CN disclosed
CN-113173952-A Ortho-dithiol reactive therapeutic probe for drug release monitoring and preparation 济南大学 2021-07-27 CN disclosed
US-20210205259-A1 ANTI-CANCER AGENT UNIVERSITY OF WOLLONGONG (AU) 2021-07-08 US disclosed
CN-106892515-B Method for treating high-concentration organic arsenic wastewater and recycling arsenic 中国科学院生态环境研究中心 2021-03-02 CN disclosed
EP-3676282-A1 ANTI-CANCER AGENT University of Wollongong (AU) 2020-07-08 EP disclosed
CN-111344298-A Anticancer agent 伍伦贡大学 2020-06-26 CN disclosed
EP-0946556-A4 COMBINATORIAL PROCESS FOR PREPARING HYDROFUROQUINOLINE LIBRARIES LILLY CO ELI (US) 2001-07-04 EP disclosed
EP-1071958-A1 METHODS FOR SUBSTRATE-LIGAND INTERACTION SCREENING Arcaris, Inc. (US) 2001-01-31 EP disclosed
WO-2000049417-A1 METHODS FOR SUBSTRATE-LIGAND INTERACTION SCREENING ARCARIS, INC. (US) 2000-08-24 WO disclosed
WO-2000047220-A1 CONTROLLING PROTEIN LEVELS IN EUCARYOTIC ORGANISMS PROTEINIX, INC. (US) 2000-08-17 WO disclosed
EP-0946556-A1 COMBINATORIAL PROCESS FOR PREPARING HYDROFUROQUINOLINE LIBRARIES ELI LILLY AND COMPANY (US) 1999-10-06 EP disclosed
WO-1998027093-A1 COMBINATORIAL PROCESS FOR PREPARING HYDROFUROQUINOLINE LIBRARIES ELI LILLY AND COMPANY (US) 1998-06-25 WO disclosed
US-5252466-A Hybrids BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION (US) 1993-10-12 US disclosed
EP-0472658-A4 FUSION PROTEINS HAVING AN IN VIVO POST-TRANSLATIONAL MODIFICATION SITE AND METHODS OF MANUFACTURE AND PURIFICATION BIOTECHNOLOGY RES & DEV (US) 1992-08-26 EP disclosed
EP-0472658-A1 FUSION PROTEINS HAVING AN IN VIVO POST-TRANSLATIONAL MODIFICATION SITE AND METHODS OF MANUFACTURE AND PURIFICATION BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION INCORPORATED (US) 1992-03-04 EP disclosed
WO-1990014431-A1 FUSION PROTEINS HAVING AN IN VIVO POST-TRANSLATIONAL MODIFICATION SITE AND METHODS OF MANUFACTURE AND PURIFICATION BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION (US) 1990-11-29 WO disclosed